1108P Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas

Abstract

Neuroendocrine neoplasms most commonly arise from the gastroenteropancreatic (GEP) system. The WHO classification of digestive system tumors describes four main types: Neuroendocrine tumor (NET) grades 1-3 and neuroendocrine carcinoma (NEC). NECs have an aggressive biology and are often diagnosed in an advanced stage associated with poor prognosis. First-line palliative chemotherapy is commonly carboplatin or cisplatin in combination with etoposide, while in second-line capecitabine-temozolomide, FOLFIRI or FOLFOX regimens are used.